56 related articles for article (PubMed ID: 36331867)
1. Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific criteria.
Holm MB; Lenggenhager D; Detlefsen S; Sántha P; Verbeke CS
Histopathology; 2024 Jul; 85(1):171-181. PubMed ID: 38571446
[TBL] [Abstract][Full Text] [Related]
2. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
Dacic S; Travis W; Redman M; Saqi A; Cooper WA; Borczuk A; Chung JH; Glass C; Lopez JM; Roden AC; Sholl L; Weissferdt A; Posadas J; Walker A; Zhu H; Wijeratne MT; Connolly C; Wynes M; Bota-Rabassedas N; Sanchez-Espiridion B; Lee JJ; Berezowska S; Chou TY; Kerr K; Nicholson A; Poleri C; Schalper KA; Tsao MS; Carbone DP; Ready N; Cascone T; Heymach J; Sepesi B; Shu C; Rizvi N; Sonett J; Altorki N; Provencio M; Bunn PA; Kris MG; Belani CP; Kelly K; Wistuba I;
J Thorac Oncol; 2023 Oct; 18(10):1290-1302. PubMed ID: 37702631
[TBL] [Abstract][Full Text] [Related]
3. Renal tumour scoring systems: How useful are they?
Kapoor A
Can Urol Assoc J; 2015; 9(1-2):46-7. PubMed ID: 25737755
[No Abstract] [Full Text] [Related]
4. Involvement of the Gut Microbiome in the Local and Systemic Immune Response to Pancreatic Ductal Adenocarcinoma.
Halle-Smith JM; Pearce H; Nicol S; Hall LA; Powell-Brett SF; Beggs AD; Iqbal T; Moss P; Roberts KJ
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473357
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis.
Leonhardt CS; Hank T; Pils D; Gustorff C; Sahora K; Schindl M; Verbeke CS; Strobel O; Klaiber U
Int J Surg; 2024 Jan; 110(1):453-463. PubMed ID: 38315795
[TBL] [Abstract][Full Text] [Related]
6. [Histopathologic diagnosis of solid and cystic pancreatic lesions with a focus on ductal adenocarcinoma : A vademecum for daily practice].
Esposito I; Yavas A; Häberle L
Pathologie (Heidelb); 2024 Feb; 45(1):5-18. PubMed ID: 38191761
[TBL] [Abstract][Full Text] [Related]
7. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer.
Stoop TF; Theijse RT; Seelen LWF; Groot Koerkamp B; van Eijck CHJ; Wolfgang CL; van Tienhoven G; van Santvoort HC; Molenaar IQ; Wilmink JW; Del Chiaro M; Katz MHG; Hackert T; Besselink MG;
Nat Rev Gastroenterol Hepatol; 2024 Feb; 21(2):101-124. PubMed ID: 38036745
[TBL] [Abstract][Full Text] [Related]
8. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma.
Saillard C; Delecourt F; Schmauch B; Moindrot O; Svrcek M; Bardier-Dupas A; Emile JF; Ayadi M; Rebours V; de Mestier L; Hammel P; Neuzillet C; Bachet JB; Iovanna J; Dusetti N; Blum Y; Richard M; Kermezli Y; Paradis V; Zaslavskiy M; Courtiol P; Kamoun A; Nicolle R; Cros J
Nat Commun; 2023 Jun; 14(1):3459. PubMed ID: 37311751
[TBL] [Abstract][Full Text] [Related]
9. Call for better response evaluation after neoadjuvant therapy in pancreatic cancer.
Zaharia C; Søreide K
Br J Surg; 2023 Feb; 110(3):294-296. PubMed ID: 36630676
[No Abstract] [Full Text] [Related]
10. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
Karamitopoulou E; Thies S; Zlobec I; Ott K; Feith M; Slotta-Huspenina J; Lordick F; Becker K; Langer R
Am J Surg Pathol; 2014 Nov; 38(11):1551-6. PubMed ID: 25140894
[TBL] [Abstract][Full Text] [Related]
12. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy.
Janssen BV; Tutucu F; van Roessel S; Adsay V; Basturk O; Campbell F; Doglioni C; Esposito I; Feakins R; Fukushima N; Gill AJ; Hruban RH; Kaplan J; Koerkamp BG; Hong SM; Krasinskas A; Luchini C; Offerhaus J; Sarasqueta AF; Shi C; Singhi A; Stoop TF; Soer EC; Thompson E; van Tienhoven G; Velthuysen MF; Wilmink JW; Besselink MG; Brosens LAA; Wang H; Verbeke CS; Verheij J;
Mod Pathol; 2021 Jan; 34(1):4-12. PubMed ID: 33041332
[TBL] [Abstract][Full Text] [Related]
13. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1).
Janssen BV; van Roessel S; van Dieren S; de Boer O; Adsay V; Basturk O; Brosens L; Campbell F; Chatterjee D; Chou A; Doglioni C; Esposito I; Feakins R; Fuchs TL; Fukushima N; Gill AJ; Hong SM; Hruban RH; Kaplan J; Krasinkas A; Luchini C; Shi C; Singhi A; Thompson E; Velthuysen MF; Besselink MG; Verheij J; Wang H; Verbeke C; Fariña A;
Br J Surg; 2022 Dec; 110(1):67-75. PubMed ID: 36331867
[TBL] [Abstract][Full Text] [Related]
14. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review.
van Roessel S; Janssen BV; Soer EC; Fariña Sarasqueta A; Verbeke CS; Luchini C; Brosens LAA; Verheij J; Besselink MG
Br J Surg; 2021 Mar; 108(2):119-127. PubMed ID: 33711148
[TBL] [Abstract][Full Text] [Related]
15. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.
N Kalimuthu S; Serra S; Dhani N; Hafezi-Bakhtiari S; Szentgyorgyi E; Vajpeyi R; Chetty R
J Clin Pathol; 2017 Mar; 70(3):237-243. PubMed ID: 27681847
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
